EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Modulating immune toxicity in ulcerative colitis using a small molecule RAB27A inhibitor

Meital Ben-David-Naim, Dan Bijaoui, Naomi Iluz, Julian Adams, Daryl C Drummond, Yatin Mankan, Christina H Eng, Jeremy W Herzog, Simon Gray, Ryan Balfour Sartor, Zvi G Fridlender, Seth J Salpeter iD und 1 weitere

Inflammatory Bowel Diseases · 2026

DOI: 10.1093/ibd/izag170 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, 2026. Verfasst von Meital Ben-David-Naim und 12 weiteren Autor:innen. Beteiligte Einrichtung: Immunyx Pharma, JBP Minrav Building, Jerusalem, 91120, Israel. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Neutrophils, rab27 GTP-Binding Proteins. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIDDK NIH HHS, Crohn's and Colitis Foundation. S.G. received support from National Institutes of Health, Small Business Innovation Research (SBIR).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Recent evidence has shown that ulcerative colitis patients with increased neutrophil biomarkers are linked to complicated disease and refractory response. In the pathology of colitis, neutrophils are recruited to the colon and yield acute damage via reactive oxygen species (ROS), degranulation, and neutrophil extracellular traps (NETosis). RAB27A is a regulator of intracellular membrane trafficking and has been shown to play a role in neutrophil activation by enabling the increased release of proteolytic granules and ROS. Studies have shown significant upregulation of RAB27A expression in biopsies of moderate and severe ulcerative colitis patients, while preclinical studies genetically deleting RAB27A in ulcerative colitis models have shown improved outcomes.

Methods

To evaluate the impact of RAB27A inhibition in ulcerative colitis and lower activated neutrophil toxicity in the disease, we developed IMYX-3, a first-in-class small molecule oral inhibitor of RAB27A activity and applied it to the study of diseased neutrophils and models.

Results

IMYX-3 lowers neutrophil ROS, degranulation, NETosis, and cytokine secretion. Preclinical efficacy was demonstrated in dextran sulfate sodium and Il10−/− mouse models, in which IMYX-3 treatment led to improved colon length, reduced systemic inflammation, lower levels of activated neutrophil function, and comparable disease outcomes compared with standard-of-care control mice. In vitro toxicity profiling as well as pharmacokinetic and toxicology studies in rodents and canines showed a favorable drug profile, with no significant adverse events observed at doses up to 30 times the predicted therapeutic range.

Conclusion

IMYX-3 effectively inhibits RAB27A activation in neutrophils, yielding improved outcomes in preclinical disease models with no major safety concerns.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeNeutrophilsrab27 GTP-Binding ProteinsAnimalsMiceDisease Models, AnimalDextran SulfateHumansReactive Oxygen SpeciesExtracellular TrapsMice, KnockoutCytokinesMice, Inbred C57BLNeutrophil Activation

Stichwörter der Autor:innen

RAB27Aneutrophilstherapeutics

Substanzen

rab27 GTP-Binding ProteinsDextran SulfateReactive Oxygen SpeciesCytokines

Autor:innen und Institutionen

  • Immunyx Pharma, JBP Minrav Building, Jerusalem, 91120, Israel.
  • Department of Developmental Biology and Cancer Research, Institute for Medical Research Israel Canada, Hebrew University Medical School, Jerusalem, 91120, Israel.
  • Immunyx Pharma USA, New York, NY, 10013, United States.
  • Center for Gastrointestinal Biology and Disease, Division of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina, Chapel Hill, NC, 27599-7032, United States.
  • National Gnotobiotic Rodent Resource Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
  • Institute of Pulmonary Medicine, Hadassah-Hebrew University Medical Center, Jerusalem, 91120, Israel.

ORCID-Profile: Seth J Salpeter, Zvi Granot

Förderung

  • NIDDK NIH HHS
  • Crohn's and Colitis Foundation. S.G. received support from National Institutes of Health
  • Small Business Innovation Research (SBIR)
  • Crohn's and Colitis Foundation IBD Ventures
  • NIH HHS
  • National Institutes of Health (NIH)
  • Crohn's and Colitis Foundation
  • ImmunyX

Zitieren

APA

Ben-David-Naim, M., Bijaoui, D., Iluz, N., Adams, J., Drummond, D. C., Mankan, Y., Eng, C. H., Herzog, J. W., Gray, S., Sartor, R. B., Fridlender, Z. G., Salpeter, S. J., & Granot, Z. (2026). Modulating immune toxicity in ulcerative colitis using a small molecule RAB27A inhibitor. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izag170

Vancouver

Ben-David-Naim M, Bijaoui D, Iluz N, Adams J, Drummond DC, Mankan Y, et al. Modulating immune toxicity in ulcerative colitis using a small molecule RAB27A inhibitor. Inflammatory Bowel Diseases. 2026. doi:10.1093/ibd/izag170

BibTeX
@article{BenDavidNaim2026,
  author = {Ben-David-Naim, Meital and Bijaoui, Dan and Iluz, Naomi and Adams, Julian and Drummond, Daryl C and Mankan, Yatin and Eng, Christina H and Herzog, Jeremy W and Gray, Simon and Sartor, Ryan Balfour and Fridlender, Zvi G and Salpeter, Seth J and Granot, Zvi},
  title = {Modulating immune toxicity in ulcerative colitis using a small molecule RAB27A inhibitor},
  journal = {Inflammatory Bowel Diseases},
  year = {2026},
  doi = {10.1093/ibd/izag170}
}
Kostenlos starten →